Epstein-Barr Virus and breast cancer: State of the evidence for viral carcinogenesis

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 5, 2004, Pages 688-697

  Glaser, Sally L ^a   Hsu, Joe L ^b   Gulley, Margaret L ^c  

^a NORTHERN CALIFORNIA CANCER CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HERPES VIRUS; HUMAN; LABORATORY TEST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; VIRUS CARCINOGENESIS; VIRUS DETECTION;

BREAST NEOPLASMS; COMORBIDITY; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 2942519289     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute, 2002.
2. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ ethnic groups. Cancer Causes Control 2001;12:703-11.
3. Adami HO, Signorello LB, Trichopoulos D. Towards an understanding of breast cancer etiology. Semin Cancer Biol 1998;8:255-62.
4. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas 2001;38:103-13.
5. Henderson BE, Pike MC, Bernstein L, Ross RK. Breast cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996. p. 3-16.
6. Rebbeck TR. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 1999;86:2493-501.
7. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013-20.
8. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 2000;92:1126-35.
9. Madigan MP, Ziegler RG, Benichou J. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87:1681-5.
10. Mezzetti M, La Vecchia C, Decarli A, Boyle P, Talamini R, Franceschi S. Population attributable risk for breast cancer: diet, nutrition, and physical exercise. J Natl Cancer Inst 1998;90:389-94.
11. Serraino D, Piselli P, Scognamiglio P. Viral infections and cancer: epidemiological aspects. J Biol Regul Homeost Agents 2001;15:224-8.
12. Pogo BG, Holland JF. Possibilities of a viral etiology for human breast cancer. A review. Biol Trace Elem Res 1997;56:131-42.
13. Wang Y, Pelisson I, Melana SM, Holland JF, Pogo BG. Detection of MMTV-like LTR and LTR-env gene sequences in human breast cancer. Int J Oncol 2001;18:1041-4.
14. Labat ML. Possible retroviral etiology of human breast cancer. Biomed Pharmacother 1998;52:6-12.
15. Labrecque LG, Barnes DM, Fentiman IS, Griffin BE. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res 1995;55:39-45.
16. Khanna R, Tellam J, Duraiswamy J, Cooper L. Immunotherapeutic strategies for EBV-associated malignancies. Trends Mol Med 2001;7:270-6.
17. Fan H, Gulley ML. Epstein-Barr viral load measurement as a marker of EBV-related disease. Mol Diagn 2001;6:279-289.
18. Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999;170:49-64.
19. Gaffey MJ, Frierson HF Jr, Mills SE, et al. Medullary carcinoma of the breast. Identification of lymphocyte subpopulations and their significance. Mod Pathol 1993;6:721-8.
20. Horiuchi K, Mishima K, Ohsawa M, Aozasa K. Carcinoma of stomach and breast with lymphoid stroma: localisation of Epstein-Barr virus. J Clin Pathol 1994;47:538-40.
21. Luqmani YA, Shousha S. Presence of Epstein-Barr virus in breast carcinoma. Int J Oncol 1995;6:899-903.
22. Lespagnard L, Cochaux P, Larsimont D, Degeyter M, Velu T, Heimann R. Absence of Epstein-Barr virus in medullary carcinoma of the breast as demonstrated by immunophenotyping, in situ hybridization and polymerase chain reaction. Am J Clin Pathol 1995;103:449-52.
23. Chu JS, Chen CC, Chang KJ. In situ detection of Epstein-Barr virus in breast cancer. Cancer Lett 1998;124:53-7.
24. Glaser SL, Ambinder RF, DiGiuseppe JA, Horn-Ross PL, Hsu JL. Absence of Epstein-Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. Int J Cancer 1998;75:555-8.
25. Bonnet M, Guinebretiere JM, Kremmer E, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999;91:1376-81.
26. Brink AATP, van den Brule AJC, van Diest P, Meijer CJLM. Re: Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 2000;92:655-6.
27. McCall SA, Lichy JH, Bijwaard KE, Aguilera NS, Chu WS, Taubenberger JK. Epstein-Barr virus detection in ductal carcinoma of the breast. J Natl Cancer Inst 2001;93:148-50.
28. Dadmanesh F, Peterse JL, Sapino A, Fonelli A, Eusebi V. Lymphoepithelioma-like carcinoma of the breast: lack of evidence of Epstein-Barr virus infection. Histopathology 2001;38:54-61.
29. Fina F, Romain S, Ouafik L, et al. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. Br J Cancer 2001;84:783-90.
30. Kijima Y, Hokita S, Takao S, et al. Epstein-Barr virus involvement is mainly restricted to lymphoepithelial type of gastric carcinoma among various epithelial neoplasms. J Med Virol 2001;64:513-8.
31. Chu PG, Chang KL, Chen YY, Chen WG, Weiss LM. No significant association of Epstein-Barr virus infection with invasive breast carcinoma. Am J Pathol 2001;159:571-8.
32. Deshpande CG, Badve S, Kidwai N, Longnecker R. Lack of expression of the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1, and LMP2A, in breast cancer cells. Lab Invest 2002;82:1193-9.
33. Grinstein S, Preciado MV, Gattuso P, et al. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res 2002;62:4876-8.
34. Herrmann K, Niedobitek G. Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res 2003;5:R13-7.
35. Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Hematol Oncol 2000;34:27-53.
36. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields virology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. p. 2575-627.
37. Niedobitek G, Meru N, Delecluse HJ. Epstein-Barr virus infection and human malignancies. Int J Exp Pathol 2001;82:149-70.
38. Wolf H, Bogedain C, Schwarzmann F. Epstein-Barr virus and its interaction with the host. Intervirology 1993;35:26-9.
39. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/ Human Herpesvirus8. Lyon: IARC; 1997.
40. Evans AS. The spectrum of infections with Epstein-Barr virus: a hypothesis. J Infect Dis 1971;124:330-7.
41. Niederman J, Evans A. Epstein-Barr virus. In: Evans AS, Kaslow RA, editors. Viral infections of humans: epidemiology and control. New York, NY: Plenum Medical Book Company; 1997. p. 253-83.
42. Sawyer RN, Evans AS, Niederman JC, McCollum RW. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis 1971;123:263-70.
43. de-The G, Day NE, Geser A, et al. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study-a review. In: de-The G, Epstein MA, zur Hausen H, editors. Oncogenesis and herpes viruses II, IARC Scientific Publications No. 11 2. Lyon: IARC; 1975. p. 3-16.
44. Gulley ML. Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 2001;3:1-10.
45. Mueller NE. Epstein-Barr virus and Hodgkin's disease: an epidemiological paradox. Epstein-Barr Virus Rep 1997;4:1-2.
46. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995;59:387-405.
47. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1:702-3.
48. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
49. Wang D, Liebowitz D, Kieff E. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol 1988;62:2337-46.
50. Moorthy RK, Thorley-Lawson DA. Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. J Virol 1993;67:2637-45.
51. Staal SP, Ambinder R, Beschorner WE, Hayward GS, Mann R. A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease [see comments]. Am J Clin Pathol 1989;91:1-5.
52. Gulley ML, Eagan PA, Quintanilla-Martinez L, et al. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood 1994;83:1595-1602.
53. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986;47:883-9.
54. Gao Y, Lu YJ, Xue SA, Chen H, Wedderburn N, Griffin BE. Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus. Oncogene 2002;21:825-35.
55. Xue SA, Lampert IA, Haldane JS, Bridger JE, Griffin BE. Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger? Br J Cancer 2003;89:113-9.
56. de-The G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978;274:756-61.
57. Levine PH, Stemmermann G, Lennette ET, Hildesheim A, Shibata D, Nomura A. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. Int J Cancer 1995;60:642-4.
58. Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985;36:545-7.
59. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989;320:689-95.
60. Henle W, Ho JH, Henle G, Chau JC, Kwan HC. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy. Int J Cancer 1977;20:663-72.
61. Junker AK, Thomas EE, Radcliffe A, Forsyth RB, Davidson AG, Rymo L. Epstein-Barr virus shedding in breast milk. Am J Med Sci 1991;302:220-3.
62. Shepherd JJ, Wright DH. Burkitt's tumour presenting as bilateral swelling of the breast in women of child-bearing age. Br J Surg 1967;54:776-80.
63. Magrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 1991;13:222-46.
64. Giardini R, Piccolo C, Rilke F. Primary non-Hodgkin's lymphomas of the female breast. Cancer 1992;69:725-35.
65. Abhyankar SH, Chiang KY, McGuirk JP, et al. Late onset Epstein-Barr virus-associated lymphoproliferative disease after allogeneic bone marrow transplant presenting as breast masses. Bone Marrow Transplant 1998;21:295-7.
66. Yasui Y, Potter JD, Stanford JL, et al. Breast cancer risk and "delayed" primary Epstein-Barr virus infection. Cancer Epidemiol Biomark Prev 2001;10:9-16.
67. Altschuler EL. Re: Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999;91:2126-7.
68. Hemminki K, Dong C. Re: Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999;91:2126; discussion 2127.
69. Kleer CG, Tseng MD, Gutsch DE, et al. Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts. Mod Pathol 2002;15:759-64.
70. Speck P, Longnecker R. Infection of breast epithelial cells with Epstein-Barr virus via cell-to-cell contact. J Natl Cancer Inst 2000;92:1849-51.
71. Angeloni A, Farina A, Gentile G, et al. Epstein-Barr virus and breast cancer: search for antibodies to the novel BFRF1 protein in sera of breast cancer patients. J Natl Cancer Inst 2001;93560-1.
72. Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin's disease. Am J Clin Pathol 2002;117:259-67.
73. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997;70:375-82.
74. Preciado MV. Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma-another point of view. Breast Cancer Res 2003;5:E6.
75. Murray PG, Lissauer D, Junying J, et al. Reactivity with a monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Res 2003;63:2338-43.
76. Niedobitek G, Murray PG, Young LS. Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma-authors' response. Breast Cancer Res 2003;5:E7.
77. Daly MB, Offit K, Li F, et al. Participation in the Cooperative Family Registry for Breast Cancer Studies: issues of informed consent. J Natl Cancer Inst 2000;92:452-6.
78. Joab II. RESPONSE: re: Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 2000;92:656.
79. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol 1995;146:1355-67.
80. Magrath I, Bhatia K. Breast cancer: a new Epstein-Barr virus-associated disease? J Natl Cancer Inst 1999;91:1349-50.
81. Sugawara Y, Makuuchi M, Takada K. Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand J Gastroenterol 2000;35:981-4.
82. Chu PG, Chen YY, Chen W, Weiss LM. No direct role for Epstein-Barr virus in American hepatocellular carcinoma. Am J Pathol 2001;159:1287-92.
83. Hummel M, Anagnostopoulos I, Korbjuhn P, Stein H. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J Pathol 1995;175:263-71.
84. Pallesen G, Hamilton-Dutoit SJ, Zhou X. The association of Epstein Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. Adv Cancer Res 1993;62:179-239.
85. Ambinder RF. γ Herpesviruses and "Hit-and-Run" oncogenesis. Am J Pathol 2000;156:1-3.
86. Gan YJ, Razzouk BI, Su T, Sixbey JW. A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBER-positive Hodgkin's disease. Am J Pathol 2002;160:781-6.
87. Sixbey JW. Epstein-Barr virus DNA loss from tumor cells and the geography of Burkitt's lymphoma. Epstein-Barr Virus Rep 2000;7:37-40.
88. Griffin BE. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems. Mutat Res 2000;462:395-405.
89. Polansky H. Microcompetition with foreign DNA and the origin of chronic disease. Rochester, NY: CBCD Publishing; 2003.
90. Wong M, Pagano JS, Schiller JT, Tevethia SS, Raab-Traub N, Gruber J. New associations of human papillomavirus, simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst 2002;94:1832-6.
91. Wu XC, Hotes JL, Fulton JP, et al, editors. Cancer incidence in North America, 1995-1999. Volume I: Incidence: North American Association of Center Cancer Registries; 2002.
92. Lo YMD, Chan LYS, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
93. Lo YM, Leung SF, Chan LY, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000;60:2351-5.